Eyepoint Pharmaceuticals (EYPT) Stock Price, News & Analysis

Company Overview

Eyepoint Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company’s proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint’s commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint’s lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery. Both products leverage sustained-release technology to deliver corticosteroids directly to ocular tissues, aiming to reduce treatment frequency and improve patient compliance compared with traditional eye drop approaches.

The company secured FDA approvals for both YUTIQ and DEXYCU in late 2018 and commenced U.S. commercial launches in 2019. Eyepoint is headquartered in New York, with additional facilities supporting manufacturing and clinical development efforts. Since its inception, the company has entered into multiple licensing agreements to expand its product portfolio and explore new ophthalmic indications, while also advancing preclinical programs investigating sustained-release therapies for other retinal and anterior segment disorders.

Eyepoint is led by James A. Mazzo, who serves as Chairman, President, and Chief Executive Officer. Under his leadership, the company has built a specialized commercial organization and forged strategic collaborations to broaden its market reach. Eyepoint continues to invest in research and development to enhance its sustained-release platform and pursue additional regulatory milestones that may address unmet needs in ophthalmology.

Key Stats

• Today's Range: $11.79 to $13.00
• 50-Day Range: $11.45 to $14.84
• 52-Week Range: $9.40 to $19.11
• Volume: 1.56 million shs
• Average Volume: 1.25 million shs
• Market Capitalization: $1.08 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $43.75
• Consensus Rating: Moderate Buy

Eyepoint Pharmaceuticals Stock Analysis - MarketRank™

Eyepoint Pharmaceuticals scored higher than 63% of companies evaluated by MarketBeat, and ranked 300th out of 832 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Eyepoint Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 1 strong buy rating, 7 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Eyepoint Pharmaceuticals has a consensus price target of $43.75, representing about 240.2% upside from its current price of $12.86.

Amount of Analyst Coverage

Eyepoint Pharmaceuticals has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Eyepoint Pharmaceuticals are expected to grow in the coming year, from ($3.30) to ($2.85) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Eyepoint Pharmaceuticals is -3.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Eyepoint Pharmaceuticals is -3.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Eyepoint Pharmaceuticals has a P/B Ratio of 3.48. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

20.65% of the float of Eyepoint Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Eyepoint Pharmaceuticals has a short interest ratio ("days to cover") of 10.33, which indicates bearish sentiment.

Change versus previous month

Short interest in Eyepoint Pharmaceuticals has recently increased by 8.67%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Eyepoint Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Eyepoint Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 4.4 / 5
• News Sentiment: 1.09

News Sentiment

Eyepoint Pharmaceuticals has a news sentiment score of 1.09. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.89 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Eyepoint Pharmaceuticals this week, compared to 3 articles on an average week.

Search Interest

6 people have searched for EYPT on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.

MarketBeat Follows

4 people have added Eyepoint Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days.

Company Ownership

• Score: 0.9 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Eyepoint Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

5.13% of the stock of Eyepoint Pharmaceuticals is held by insiders.

Percentage Held by Institutions

99.41% of the stock of Eyepoint Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/06/2026
• Today: 7/30/2026
• Next Earnings (Estimated): 8/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Measuring And Control Equipment
• Current Symbol: NASDAQ:EYPT
• CIK: 1314102
• Web: eyepointpharma.com
• Phone: (617) 926-5000
• Fax: 617-926-5050
• Employees: 120
• Year Founded: 1987

Price Target and Rating

• Average Price Target for Eyepoint Pharmaceuticals: $43.75
• High Price Target: $68.00
• Low Price Target: $28.00
• Potential Upside/Downside: +240.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.89
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.50)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$231.96 million
• Net Margins: -3,566.63%
• Pretax Margin: -3,563.62%
• Return on Equity: -110.54%
• Return on Assets: -90.15%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.66
• Quick Ratio: 6.63

Sales & Book Value

• Annual Sales: $31.37 million
• Price / Sales: 34.37
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.70 per share
• Price / Book: 3.48

Miscellaneous

• Outstanding Shares: 83,840,000
• Free Float: 79,540,000
• Market Cap: $1.08 billion
• Optionable: Optionable
• Beta: 1.73